CTOs on the Move

IsoPlexis

www.isoplexis.com

 
IsoPlexis is leading a new era of functional proteomics. By identifying our most proteomically active single cells (or "superhero cells") for the first time, IsoPlexis enables researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies and at the majority of leading U.S. comprehensive cancer centers.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.isoplexis.com
  • 35 NorthEast Industrial Road
    Branford, CT USA 06405
  • Phone: 475.221.8402

Executives

Name Title Contact Details

Funding

IsoPlexis raised $25M on 05/14/2019
IsoPlexis raised $20M on 01/09/2020
IsoPlexis raised $50M on 01/07/2021
IsoPlexis raised $85M on 01/07/2021

Similar Companies

Croda

Croda is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lantern Pharma

Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials.

Marina Biotech

Marina Biotech is a Bothell, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Millendo

Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing`s Syndrome (CS).

Taiga Biotechnologies Inc

Taiga Biotechnologies is a privately-held developer of novel therapies for complex diseases including cancers, infectious agents such as HIV and influenza, and hematologic conditions.